Created in 2021, the Biotechs / Medtechs committee of YoungShareholders was built around observations shared by its members and a growing number of news items, bringing the subject of biotechnologies to the heart of collective considerations and consequently, decisions of investment for the future.

Coming from a long scientific tradition , the term biotechnology in its industrial sense only appeared in the second half of the 20th century. Heir to various but nonetheless complementary disciplines such as Biology, Pharmacy, Statistics, Medicine or Engineering, biotechnologies can be defined as ”the application of science and technology to living organisms, as well as 'to its components, products and models, to modify living or non-living materials for the production of knowledge, goods and services ”. A variety of scientific discoveries are owed to biotechnology, ranging from the production of insulin by E. coli to recent gene and cell therapies. More recently, the term Medtech (contraction of Medical Technologies) has appeared to include all the technologies allowing the development of medical devices or digital solutions for therapeutic purposes.

At the time of the COVID-19 pandemic, biotechnologies or Medtech have become subjects plunged into the heart of public and scientific debate. Often developed through public / private research partnerships, these new therapeutic techniques have become more than ever a strategic issue for the future of our societies. This is why the Biotech / Medtech Committee is committed to offering as many people as possible a rigorous and popularized analysis of current events in order to bring together a community of enthusiasts, able to understand the technical decisions that investment in this sector represents. by identifying the actors of tomorrow.